Welcome to LookChem.com Sign In|Join Free
  • or
2-(Carboxyacetamido)benzoic acid is a chemical compound with the molecular formula C10H9NO5. It is a derivative of benzoic acid and has a carboxyacetamido group attached to the benzene ring. 2-(CARBOXYACETAMIDO)BENZOIC ACID has been studied for its potential applications in the pharmaceutical industry, particularly for its anti-inflammatory and analgesic properties. It may also have uses as a drug intermediate or as a building block for the synthesis of other organic compounds. The chemical properties and biological activities of 2-(carboxyacetamido)benzoic acid make it a subject of interest for further research and potential medical applications.

53947-84-5

Post Buying Request

53947-84-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

53947-84-5 Usage

Uses

Used in Pharmaceutical Industry:
2-(Carboxyacetamido)benzoic acid is used as a pharmaceutical compound for its anti-inflammatory and analgesic properties. It may help in reducing inflammation and pain associated with various conditions.
Used as a Drug Intermediate:
2-(Carboxyacetamido)benzoic acid is used as a drug intermediate, which means it can be further processed or modified to create other pharmaceutical compounds with specific therapeutic effects.
Used as a Building Block for Organic Synthesis:
2-(Carboxyacetamido)benzoic acid is used as a building block for the synthesis of other organic compounds. Its unique structure allows it to be a valuable component in the creation of new molecules with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.
Used in Research and Development:
2-(Carboxyacetamido)benzoic acid is used in research and development for exploring its chemical properties and biological activities. This can lead to the discovery of new applications and advancements in the field of medicine and other related industries.

Check Digit Verification of cas no

The CAS Registry Mumber 53947-84-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,9,4 and 7 respectively; the second part has 2 digits, 8 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 53947-84:
(7*5)+(6*3)+(5*9)+(4*4)+(3*7)+(2*8)+(1*4)=155
155 % 10 = 5
So 53947-84-5 is a valid CAS Registry Number.

53947-84-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-[(2-carboxyacetyl)amino]benzoic acid

1.2 Other means of identification

Product number -
Other names 2-(carboxyacetamido)benzoic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:53947-84-5 SDS

53947-84-5Relevant academic research and scientific papers

The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both in Vitro and in Vivo

Zhang, Han,Yu, Peilin,Lin, Hongwei,Jin, Zefang,Zhao, Siqi,Zhang, Yi,Xu, Qingxia,Jin, Hongwei,Liu, Zhenming,Yang, Wei,Zhang, Liangren

, p. 3976 - 3996 (2021/05/04)

The transient receptor potential melastatin 2 (TRPM2) channel is associated with ischemia/reperfusion injury, inflammation, cancer, and neurodegenerative diseases. However, the limit of specific inhibitors impedes the development of TRPM2-targeted therapeutic agents. To discover more potent and selective TRPM2 inhibitors, 59 N-(p-amylcinnamoyl) anthranilic acid (ACA) derivatives were synthesized and evaluated using calcium imaging and electrophysiology approaches. Systematic structure-activity relationship studies resulted in some potent compounds inhibiting the TRPM2 channel with sub-micromolar half-maximal inhibitory concentration values. Among them, the preferred compound A23 exhibited TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showed neuroprotective activity in vitro. Following pharmacokinetic studies, A23 was further evaluated in a transient middle cerebral artery occlusion model in vivo, which significantly reduced cerebral infarction. These data indicate that A23 might serve as a useful tool for TRPM2-related research as well as a lead compound for the development of therapeutic agents for ischemic injury.

Quantitation and Taste Contribution of Sensory Active Molecules in Oat (Avena sativa L.)

Dawid, Corinna,Günther-Jordanland, Kirsten,Hofmann, Thomas

, p. 10097 - 10108 (2020/10/26)

A total of 59 taste-active molecules were quantitated and then rated for their individual taste impact on the basis of dose-over-threshold factors in oat flour (Avena sativa L.). A sensitive high-performance liquid chromatography-tandem mass spectrometry

N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites

Chandrabalan, Arundhasa,McPhillie, Martin J.,Morice, Alyn H.,Boa, Andrew N.,Sadofsky, Laura R.

supporting information, p. 141 - 156 (2019/03/17)

The transient receptor potential ankyrin 1 (TRPA1) channel is a non-selective cation channel, which detects noxious stimuli leading to pain, itch and cough. However, the mechanism(s) of channel modulation by many of the known, non-reactive modulators has not been fully elucidated. N-Cinnamoylanthranilic acid derivatives (CADs) contain structural elements from the TRPA1 modulators cinnamaldehyde and flufenamic acid, so it was hypothesized that specific modulators could be found amongst them and more could be learnt about modulation of TRPA1 with these compounds. A series of CADs was therefore screened for agonism and antagonism in HEK293 cells stably transfected with WT-human (h)TRPA1, or C621A, F909A or F944A mutant hTRPA1. Derivatives with electron-withdrawing and/or electron-donating substituents were found to possess different activities. CADs with inductive electron-withdrawing groups were agonists with desensitising effects, and CADs with electron-donating groups were either partial agonists or antagonists. Site-directed mutagenesis revealed that the CADs do not undergo conjugate addition reaction with TRPA1, and that F944 is a key residue involved in the non-covalent modulation of TRPA1 by CADs, as well as many other structurally distinct non-reactive TRPA1 ligands already reported.

Key Phytochemicals Contributing to the Bitter Off-Taste of Oat (Avena sativa L.)

Günther-Jordanland, Kirsten,Dawid, Corinna,Dietz, Maximilian,Hofmann, Thomas

, p. 9639 - 9652 (2017/01/12)

Sensory-directed fractionation of extracts prepared from oat flour (Avena sativa L.) followed by LC-TOF-MS, LC-MS/MS, and 1D/2D-NMR experiments revealed avenanthramides and saponins as the key phytochemicals contributing to the typical astringent and bitter off-taste of oat. Besides avenacosides A and B, two previously unreported bitter-tasting bidesmosidic saponins were identified, namely, 3-(O-α-l-rhamnopyranosyl(1→2)-[β-d-glucopyranosyl(1→3)-β-d-glucopyranosyl(1→4)]-β-d-glucopyranosid)-26-O-β-d-glucopyranosyl-(25R)-furost-5-ene-3β,22,26-triol, and 3-(O-α-l-rhamnopyranosyl(1→2)-[β-d-glucopyranosyl(1→4)]-β-d-glucopyranosid)-26-O-β-d-glucopyranosyl-(25R)-furost-5-ene-3β,22,26-triol. Depending on the chemical structure of the saponins and avenanthramides, sensory studies revealed human orosensory recognition thresholds of these phytochemicals to range between 3 and 170 μmol/L.

3′,4′-Bis-difluoromethoxycinnamoylanthranilate (FT061): An orally-active antifibrotic agent that reduces albuminuria in a rat model of progressive diabetic nephropathy

Williams, Spencer J.,Zammit, Steven C.,Cox, Alison J.,Shackleford, David M.,Morizzi, Julia,Zhang, Yuan,Powell, Andrew K.,Gilbert, Richard E.,Krum, Henry,Kelly, Darren J.

supporting information, p. 6868 - 6873 (2014/01/06)

Cinnamoylanthranilates including tranilast have been identified as promising antifibrotics that can reduce fibrosis occurring in the kidney during diabetes, thereby delaying and/or preventing kidney dysfunction. Structure-activity relationships aimed at improving potency and metabolic stability have led to the discovery of FT061. This compound, which bears a bis-difluoromethoxy catechol, attenuates TGF-β-stimulated production of collagen in cultured renal mesangial cells (approx 50% at 3 μM). When dosed orally at 20 mg/kg to male Sprague Dawley rats, FT061 exhibited a high bioavailability (73%), Cmax of 200 μM and Tmax of 150 min, and a half-life of 5.4 h. FT061 reduced albuminuria when orally dosed in rats at 200 mg kg/day in a late intervention study of a rat model of progressive diabetic nephropathy.

FUSED RING ANALOGUES OF ANTI-FIBROTIC AGENTS

-

Page/Page column 78, (2011/05/06)

The present invention relates to arylcarbonyl and heteroarylcarbonyl anthranilate compounds that may be useful as anti-fibrotic agents. The present invention also relates to methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment disorders.

HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS

-

Page/Page column 34-35, (2009/07/25)

The present invention relates to halogenated compounds of formula (I) with the substituents as described within the specification. The compounds may be useful as anti-fibrqtic agents. The present invention also relates to methods for their preparation.

Evaluation and optimization of antifibrotic activity of cinnamoyl anthranilates

Zammit, Steven C.,Cox, Alison J.,Gow, Renae M.,Zhang, Yuan,Gilbert, Richard E.,Krum, Henry,Kelly, Darren J.,Williams, Spencer J.

supporting information; experimental part, p. 7003 - 7006 (2010/07/08)

Tranilast is an anti-inflammatory drug in use for asthma and atopic dermatitis. In studies over the last decade it has been revealed that tranilast can reduce fibrosis occurring in the kidney during diabetes, thereby delaying and/or preventing kidney dysfunction. We report a structure-activity study aimed at optimizing the antifibrotic activity of tranilast. A series of cinnamoyl anthranilates were prepared and assessed for their ability to prevent TGF-β-stimulated production of collagen in cultured renal mesangial cells. We reveal derivatives with improved potency and reduced cellular toxicity relative to tranilast. 3-Methoxy-4-propargyloxycinnamoyl anthranilate reduces albuminuria in a rat model of progressive diabetes, and thus has potential as an innovative treatment for diabetic nephropathy.

THERAPEUTIC COMPOUNDS

-

Page/Page column 41; 42, (2008/06/13)

Substituted cinnamoyl anthranilate compounds exhibiting anti-fibrotic activity; or derivatives thereof, analogues thereof, pharmaceutically acceptable salts thereof, and metabolites thereof; with the proviso that the compound is not Tranilast.

A simple two-step synthesis of avenanthramides, constituents of oats (Avena sativa L)

Kamat, Shrivallabh P.,Parab, Sulaksha J.

, p. 2074 - 2078 (2008/09/19)

A simple two-step general procedure has been developed to prepare naturally occurring and synthetic avenanthramides, constituents of oats (Avena sativa L). Reaction of anthranilic acid 1 with Meldrum's acid 2 gives half amide of malonic acid 3 which on condensation with different benzaldehyde derivatives 4a-m gives avenanthramides 5a-m of which 5a-d are natural, 5e-g are their methyl ethers and 5h-m are synthetic.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 53947-84-5